Clene (NASDAQ:CLNN) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Clene (NASDAQ:CLNN – Free Report) in a report issued on Tuesday, Benzinga reports. The brokerage currently has a $7.00 price target on the stock. Separately, Benchmark reissued a buy rating and set a $5.00 target price on shares of Clene in a research note on Thursday, […]

Related Keywords

, Nasdaq , Exchange Commission , Silverarc Capital Management , Clene Inc , Clene Company Profile , Free Report , Get Free Report , Capital Management , Multiple Sclerosis , Clene Daily ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.